产品
编 号：F161235
分子式：C96H140N20O25S
分子量：2006.32
分子式：C96H140N20O25S
分子量：2006.32
产品类型
规格
价格
是否有货
结构图
CAS No: 143113-45-5
产品详情
生物活性：
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research12.
体内研究：
BQ-3020 (3 mg/kg 皮下注射, 单次给药) 可使癌痛小鼠模型在注射后 3 小时内的癌痛减轻约 50%。Animal Model:Cancer pain mouse model
Dosage:3 mg/kg
Administration:Injected subcutaneously at the site of the greatest tumor development
Result:Attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection
体外研究：
BQ-3020（0.01–300 nM，7分钟）对 PhE 预收缩的尿路上皮剥离组织产生浓度依赖性松弛。BQ-3020 (0.01–200 nM，20 min) 通过抑制 ETB 受体引起兔肺动脉剂量依赖性血管收缩，其 EC50 值为 0.57 nM。
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research12.
体内研究：
BQ-3020 (3 mg/kg 皮下注射, 单次给药) 可使癌痛小鼠模型在注射后 3 小时内的癌痛减轻约 50%。Animal Model:Cancer pain mouse model
Dosage:3 mg/kg
Administration:Injected subcutaneously at the site of the greatest tumor development
Result:Attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection
体外研究：
BQ-3020（0.01–300 nM，7分钟）对 PhE 预收缩的尿路上皮剥离组织产生浓度依赖性松弛。BQ-3020 (0.01–200 nM，20 min) 通过抑制 ETB 受体引起兔肺动脉剂量依赖性血管收缩，其 EC50 值为 0.57 nM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备